In a collaboration called “Prospective Measures of Outcome in Rapidly Progressive Dementia,” Amprion will perform the SYNTap® Biomarker Test on a mixed cohort of approximately 200 CSF samples from well-characterized, clinically diagnosed RPD patients and healthy controls. This research is expected to shed light on the role alpha-Synuclein (αS), a misfolded protein, plays in the neurodegenerative condition of RPD.
“We’re excited to participate in this scientific collaboration with Mayo Clinic in Florida to explore the biomarker influence of misfolded Synuclein associated with RPD,” Amprion CEO Russ Lebovitz, MD/Ph.D., remarks. “This study will help us gain valuable insights to advance the molecular understanding of this highly elusive, complex, and devastating neurological condition,” added Dr. Lebovitz.
This collaboration aims to define further the characterization, clinical evaluation, and underlying synucleinopathy in RPD. In doing so, we aim to improve the diagnostic strategies to serve this patient population better.
Amprion will attend AAIC in San Diego (7/31-8/4), and we look forward to connecting with medical professionals during this conference. Visit us at booth #305 for collaborative exchange.
A leader in Prion Detection Science™, Amprion innovates biomarker testing for brain diseases. Our SYNTap® Biomarker Test helps doctors diagnose Lewy Body Variant of Alzheimer’s Disease, Parkinson’s Disease, and Lewy Body Dementia. Amprion strives to accelerate precision medicine for neurodegenerative diseases through molecular testing.